New pill takes aim at genetic weakness in tough blood cancers

NCT ID NCT07155226

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This early-phase study is testing an experimental oral drug called AZD3632 in about 84 people with advanced blood cancers (acute leukemias or myelodysplastic syndromes) that have certain genetic changes. The main goals are to check the drug's safety and find the right dose, while also looking for early signs that it might help control the disease. Participants receive the drug alone or with another medication to see how the body processes it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD3632 (an experimental oral drug)
What this could lead to: If it works, this could point toward a new treatment option for people with certain hard-to-treat blood cancers.
What could go wrong: This is an early-phase trial with only 84 participants, so it is too soon to know if the drug is safe or effective. Many experimental cancer drugs fail in early testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloblastic leukemia with maturation acute myeloid leukemia adult acute lymphoblastic leukemia childhood acute lymphoblastic leukemia myelodysplastic syndrome Myelodysplastic Syndromes Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKAEMIA ACUTE MYELOID LEUKAEMIA HIGHER-RISK MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Research Site
RECRUITING

Decatur, Illinois, 62526, United States
Research Site
NOT_YET_RECRUITING

New York, New York, 10065, United States
Research Site
NOT_YET_RECRUITING

Chapel Hill, North Carolina, 27599, United States
Research Site
RECRUITING

Durham, North Carolina, 27705, United States
Research Site
SUSPENDED

Portland, Oregon, 97239, United States
Research Site
RECRUITING

Houston, Texas, 77030, United States
Research Site
SUSPENDED

Fitzroy, 3065, Australia
Research Site
SUSPENDED

Perth, WA 6000, Australia
Research Site
SUSPENDED

Toronto, Ontario, M5G 2M9, Canada
Research Site
SUSPENDED

Montreal, Quebec, H3T 1E2, Canada
Research Site
RECRUITING

Copenhagen, 2100, Denmark
Research Site
RECRUITING

Dresden, 01307, Germany
Research Site
RECRUITING

Frankfurt A. Main, 60590, Germany
Research Site
RECRUITING

Halle, 06097, Germany
Research Site
RECRUITING

Heidelberg, 69120, Germany
Research Site
RECRUITING

München, 81377, Germany
Research Site
RECRUITING

Ulm, 89081, Germany
Research Site
RECRUITING

Bologna, 40138, Italy
Research Site
RECRUITING

Ravenna, 48121, Italy
Research Site
RECRUITING

Bunkyō City, 113-8677, Japan
Research Site
NOT_YET_RECRUITING

Kashiwa, 277-8577, Japan
Research Site
RECRUITING

Okayama, 700-8558, Japan
Research Site
RECRUITING

Seoul, 06351, South Korea
Research Site
RECRUITING

Seoul, 06591, South Korea
Research Site
RECRUITING

Seoul, 110-744, South Korea
Research Site
RECRUITING

Edinburgh, EH4 2XU, United Kingdom
Research Site
RECRUITING

London, EC1A 7BE, United Kingdom
Research Site
RECRUITING

London, SE5 9RS, United Kingdom
Research Site
RECRUITING

Manchester, M20 4BX, United Kingdom
Research Site
SUSPENDED

Newcastle, NE7 7DN, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.